HCPCS code Q5129: Vegzelma injection, per 10 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What Q5129 covers

Q5129 identifies bevacizumab-adcd, marketed as Vegzelma, a biosimilar of bevacizumab. Oncology practices typically report it for the drug administered by intravenous infusion as part of a cancer treatment regimen. Bevacizumab is used for several cancers, with the treatment combination depending on the cancer and regimen. The code identifies the specific biosimilar supplied, rather than bevacizumab products with different biosimilar names.

CMS assigns this code physician fee schedule status E, excluding it from the physician fee schedule. When Medicare covers the drug, it is treated as a Part B drug and generally priced using CMS’s quarterly Average Sales Price drug files; coverage is left to the Medicare contractor’s judgment. Each billing unit represents 10 mg of bevacizumab-adcd, so the reported units reflect the administered amount in 10 mg increments. The drug code identifies the medication; the infusion service is a separate service.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where Q5129 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

Q5129 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the Q5129 rate is calculated

Each of Q5129’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for Q5129

Q5129 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

Q5129 compared with similar codes

How to choose

Q5118Zirabev injectionPer 10 mg

Q5118 identifies Zirabev, another bevacizumab biosimilar. Q5129 identifies Vegzelma; the product actually administered determines which code applies.

Q5126Alymsys injectionPer 10 mg

Q5126 identifies Alymsys, a different bevacizumab biosimilar. Use Q5129 for Vegzelma, not simply because both products contain a bevacizumab biosimilar.

J9035BevacizumabPer 10 mg

J9035 identifies bevacizumab, while Q5129 identifies the bevacizumab-adcd biosimilar Vegzelma. Choose based on the specific drug product administered.

Codes related to Q5129

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates